High Finance with Peter Su ft. Daniela Williams: Chief Growth Officer: Paylient

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Latest News

BREAKING: MAPS Wins FDA Approval for Clinical Trials of Medical Cannabis

HCN News Team2024-11-20T17:21:05-08:00November 20th, 2024|

SAN JOSE-- The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the Multidisciplinary Association for Psychedelic Studies (MAPS)’ Phase 2 study of smoked cannabis in Veterans for the treatment of PTSD ...

Curaleaf Secures Massachusetts’ First Cannabis Research License

HCN News Team2024-11-20T06:50:37-08:00November 20th, 2024|

LOS ANGELES- In a significant development for the cannabis industry, Curaleaf Holdings, Inc., a leading multistate operator, has secured Massachusetts' inaugural cannabis research facility license. The Massachusetts Cannabis Control Commission (CCC) unanimously approved the license ...

Cybin Reports 79% Remission in MDD with CYB003, Prepares for Phase 3 Trials

HCN News Team2024-11-20T06:49:31-08:00November 20th, 2024|

LOS ANGELES- Cybin Inc., has announced promising results from its Phase 2 study of CYB003, a proprietary deuterated psilocybin analog developed for the treatment of major depressive disorder (MDD). The study demonstrated that 79% of ...

High Finance with Peter Su ft. Daniela Williams: Chief Growth Officer: Paylient

About the Author: HCN News Team

Latest News

BREAKING: MAPS Wins FDA Approval for Clinical Trials of Medical Cannabis

Curaleaf Secures Massachusetts’ First Cannabis Research License

Cybin Reports 79% Remission in MDD with CYB003, Prepares for Phase 3 Trials

Navigate

Legal

About

HCN Media Group | 171 Pier Avenue, Suite 177, Santa Monica, California, 90405

Enter your email & receive instant access to Uncovering the Hidden Costs of Employee Non-Compliance

If you are not automatically redirected after submission, please email us at [email protected].

By providing your email address, you agree to our Privacy Policy & Terms of Use and consent to receive emails from Paylient and Highly Capitalized.

We are committed to protecting your privacy with responsible data practices. We will NEVER sell nor share your personal information with third parties outside of the producers of this eBook — Paylient and Highly Capitalized.

High Finance with Peter Su ft. Daniela Williams: Chief Growth Officer: Paylient

About the Author: HCN News Team

Share This Story, Choose Your Platform!

Related Posts

Latest News

BREAKING: MAPS Wins FDA Approval for Clinical Trials of Medical Cannabis

Curaleaf Secures Massachusetts’ First Cannabis Research License

Cybin Reports 79% Remission in MDD with CYB003, Prepares for Phase 3 Trials

Navigate

Legal

About

HCN Media Group | 171 Pier Avenue, Suite 177, Santa Monica, California, 90405